Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 682

1.

Vaccines: An achievement of civilization, a human right, our health insurance for the future.

Rappuoli R, Santoni A, Mantovani A.

J Exp Med. 2018 Dec 3. pii: jem.20182160. doi: 10.1084/jem.20182160. [Epub ahead of print]

PMID:
30510147
2.

Meningococcal B vaccine: The journey from research to real world experience.

Rappuoli R, Pizza M, Masignani V, Vadivelu-Pechai K.

Expert Rev Vaccines. 2018 Nov 20. doi: 10.1080/14760584.2018.1547637. [Epub ahead of print]

PMID:
30457407
3.

Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella.

Micoli F, Rondini S, Alfini R, Lanzilao L, Necchi F, Negrea A, Rossi O, Brandt C, Clare S, Mastroeni P, Rappuoli R, Saul A, MacLennan CA.

Proc Natl Acad Sci U S A. 2018 Oct 9;115(41):10428-10433. doi: 10.1073/pnas.1807655115. Epub 2018 Sep 27.

4.

Glycoconjugate vaccines: Principles and mechanisms.

Rappuoli R.

Sci Transl Med. 2018 Aug 29;10(456). pii: eaat4615. doi: 10.1126/scitranslmed.aat4615. Review.

PMID:
30158151
5.

Farewell Stan Stanley Falkow: 1934-2018.

Cabello FC, Cohen SN, Curtiss R 3rd, Dougan G, van Embden J, Finlay BB, Heffron F, Helinski D, Hull R, Hull S, Isberg R, Kopecko DJ, Levy S, Mekalanos J, Ortiz JM, Rappuoli R, Roberts MC, So M, Timmis KN.

Environ Microbiol. 2018 Jul;20(7):2322-2333. doi: 10.1111/1462-2920.14308. Epub 2018 Aug 26. No abstract available.

PMID:
30146753
6.

Short-term and mid-term solutions for influenza vaccines.

Hanon E, Van der Most R, Del Giudice G, Rappuoli R.

Lancet Infect Dis. 2018 Aug;18(8):832-833. doi: 10.1016/S1473-3099(18)30404-3. No abstract available.

PMID:
30064669
7.

Efficacy, immunogenicity, and safety of a parenteral vaccine against Helicobacter pylori in healthy volunteers challenged with a Cag-positive strain: a randomised, placebo-controlled phase 1/2 study.

Malfertheiner P, Selgrad M, Wex T, Romi B, Borgogni E, Spensieri F, Zedda L, Ruggiero P, Pancotto L, Censini S, Palla E, Kanesa-Thasan N, Scharschmidt B, Rappuoli R, Graham DY, Schiavetti F, Del Giudice G.

Lancet Gastroenterol Hepatol. 2018 Oct;3(10):698-707. doi: 10.1016/S2468-1253(18)30125-0. Epub 2018 Jul 2.

PMID:
30042064
8.

Changing Priorities in Vaccinology: Antibiotic Resistance Moving to the Top.

Tagliabue A, Rappuoli R.

Front Immunol. 2018 May 30;9:1068. doi: 10.3389/fimmu.2018.01068. eCollection 2018. Review.

9.

Role of O-Acetylation in the Immunogenicity of Bacterial Polysaccharide Vaccines.

Berti F, De Ricco R, Rappuoli R.

Molecules. 2018 Jun 2;23(6). pii: E1340. doi: 10.3390/molecules23061340. Review.

10.

Correlates of adjuvanticity: A review on adjuvants in licensed vaccines.

Del Giudice G, Rappuoli R, Didierlaurent AM.

Semin Immunol. 2018 May 22. pii: S1044-5323(18)30051-4. doi: 10.1016/j.smim.2018.05.001. [Epub ahead of print] Review.

11.

3. How comprehensive can we be in the economic assessment of vaccines?

Standaert B, Rappuoli R.

J Mark Access Health Policy. 2017 Aug 31;5(1):1336044. doi: 10.1080/20016689.2017.1336044. eCollection 2017. Review.

12.

2. How is the economic assessment of vaccines performed today?

Standaert B, Rappuoli R.

J Mark Access Health Policy. 2017 Aug 31;5(1):1335163. doi: 10.1080/20016689.2017.1335163. eCollection 2017. Review.

13.

Towards a more comprehensive approach for a total economic assessment of vaccines?: 1. The building blocks for a health economic assessment of vaccination.

Standaert B, Rappuoli R.

J Mark Access Health Policy. 2017 Aug 31;5(1):1335162. doi: 10.1080/20016689.2017.1335162. eCollection 2017. Review.

14.

Sustainable vaccine development: a vaccine manufacturer's perspective.

Rappuoli R, Hanon E.

Curr Opin Immunol. 2018 Aug;53:111-118. doi: 10.1016/j.coi.2018.04.019. Epub 2018 May 8. Review.

15.

Human protective response induced by meningococcus B vaccine is mediated by the synergy of multiple bactericidal epitopes.

Giuliani M, Bartolini E, Galli B, Santini L, Lo Surdo P, Buricchi F, Bruttini M, Benucci B, Pacchiani N, Alleri L, Donnarumma D, Pansegrau W, Peschiera I, Ferlenghi I, Cozzi R, Norais N, Giuliani MM, Maione D, Pizza M, Rappuoli R, Finco O, Masignani V.

Sci Rep. 2018 Feb 27;8(1):3700. doi: 10.1038/s41598-018-22057-7.

16.

Deploy vaccines to fight superbugs.

Rappuoli R, Bloom DE, Black S.

Nature. 2017 Dec 14;552(7684):165-167. doi: 10.1038/d41586-017-08323-0. No abstract available.

PMID:
29239371
17.

Will Systems Biology Deliver Its Promise and Contribute to the Development of New or Improved Vaccines? Systems Biology Views of Vaccine Innate and Adaptive Immunity.

Rappuoli R, Siena E, Finco O.

Cold Spring Harb Perspect Biol. 2018 Aug 1;10(8). pii: a029256. doi: 10.1101/cshperspect.a029256. Review.

PMID:
29038117
18.

Improving accountability in vaccine decision-making.

Timmis JK, Black S, Rappuoli R.

Expert Rev Vaccines. 2017 Nov;16(11):1057-1066. doi: 10.1080/14760584.2017.1382358. Epub 2017 Oct 9. Review.

PMID:
28929818
19.

Editorial overview: Preventive and therapeutic vaccines: Vaccination against viral disease - current advances and challenges.

Rappuoli R, Sutter G.

Curr Opin Virol. 2017 Apr;23:vi-viii. doi: 10.1016/j.coviro.2017.06.001. No abstract available.

PMID:
28622999
20.

An unwanted guest: Neisseria meningitidis - carriage, risk for invasive disease and the impact of vaccination with insight on Italy incidence.

Gianchecchi E, Piccini G, Torelli A, Rappuoli R, Montomoli E.

Expert Rev Anti Infect Ther. 2017 Jul;15(7):689-701. doi: 10.1080/14787210.2017.1333422. Epub 2017 May 29. Review.

PMID:
28524748
21.

Recombinant BCG Expressing LTAK63 Adjuvant induces Superior Protection against Mycobacterium tuberculosis.

Nascimento IP, Rodriguez D, Santos CC, Amaral EP, Rofatto HK, Junqueira-Kipnis AP, Gonçalves EDC, D'Império-Lima MR, Hirata MH, Silva CL, Winter N, Gicquel B, Mills KHG, Pizza M, Rappuoli R, Leite LCC.

Sci Rep. 2017 May 18;7(1):2109. doi: 10.1038/s41598-017-02003-9.

22.

Structure of a protective epitope of group B Streptococcus type III capsular polysaccharide.

Carboni F, Adamo R, Fabbrini M, De Ricco R, Cattaneo V, Brogioni B, Veggi D, Pinto V, Passalacqua I, Oldrini D, Rappuoli R, Malito E, Margarit IYR, Berti F.

Proc Natl Acad Sci U S A. 2017 May 9;114(19):5017-5022. doi: 10.1073/pnas.1701885114. Epub 2017 Apr 24.

23.

Emerging infectious diseases: A proactive approach.

Bloom DE, Black S, Rappuoli R.

Proc Natl Acad Sci U S A. 2017 Apr 18;114(16):4055-4059. doi: 10.1073/pnas.1701410114. Epub 2017 Apr 10.

24.

Emerging experience with meningococcal serogroup B protein vaccines.

Toneatto D, Pizza M, Masignani V, Rappuoli R.

Expert Rev Vaccines. 2017 May;16(5):433-451. doi: 10.1080/14760584.2017.1308828. Epub 2017 Apr 10. Review.

PMID:
28375029
25.

Vaccines for Staphylococcus aureus and Target Populations.

Pozzi C, Olaniyi R, Liljeroos L, Galgani I, Rappuoli R, Bagnoli F.

Curr Top Microbiol Immunol. 2017;409:491-528. doi: 10.1007/82_2016_54.

PMID:
28197738
26.

Meningococcal B Vaccine during a University Outbreak.

Rappuoli R.

N Engl J Med. 2016 Oct 20;375(16):1594-5. doi: 10.1056/NEJMc1610666. No abstract available.

PMID:
28103429
27.

Compare voting systems to improve them.

Madhavan G, Phelps C, Rappuoli R.

Nature. 2017 Jan 10;541(7636):151-153. doi: 10.1038/541151a. No abstract available.

PMID:
28079088
28.

Core values for vaccine evaluation.

Timmis JK, Rigat F, Rappuoli R.

Vaccine. 2017 Jan 20;35 Suppl 1:A57-A62. doi: 10.1016/j.vaccine.2016.11.034. Epub 2016 Dec 22.

PMID:
28017445
29.

Introduction to the vaccine supplement.

Rappuoli R.

Vaccine. 2017 Jan 20;35 Suppl 1:A1. doi: 10.1016/j.vaccine.2016.11.038. Epub 2016 Dec 22. No abstract available.

PMID:
28017437
30.

Beyond cost-effectiveness: Using systems analysis for infectious disease preparedness.

Phelps C, Madhavan G, Rappuoli R, Colwell R, Fineberg H.

Vaccine. 2017 Jan 20;35 Suppl 1:A46-A49. doi: 10.1016/j.vaccine.2016.08.090. Epub 2016 Dec 22.

PMID:
28017432
31.

Comparative Systems Analyses Reveal Molecular Signatures of Clinically tested Vaccine Adjuvants.

Olafsdottir TA, Lindqvist M, Nookaew I, Andersen P, Maertzdorf J, Persson J, Christensen D, Zhang Y, Anderson J, Khoomrung S, Sen P, Agger EM, Coler R, Carter D, Meinke A, Rappuoli R, Kaufmann SH, Reed SG, Harandi AM.

Sci Rep. 2016 Dec 13;6:39097. doi: 10.1038/srep39097.

32.

Editorial overview: Vaccines: novel technologies for vaccine development.

Rappuoli R, De Gregorio E.

Curr Opin Immunol. 2016 Aug;41:v-vii. doi: 10.1016/j.coi.2016.07.001. Epub 2016 Aug 4. No abstract available.

PMID:
27499109
33.

Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines.

Buonsanti C, Balocchi C, Harfouche C, Corrente F, Galli Stampino L, Mancini F, Tontini M, Malyala P, Bufali S, Baudner B, De Gregorio E, Valiante NM, O'Hagan DT, Rappuoli R, D'Oro U.

Sci Rep. 2016 Jul 21;6:29063. doi: 10.1038/srep29063.

34.

Multicriteria decision analysis and core values for enhancing vaccine-related decision-making.

Barocchi MA, Black S, Rappuoli R.

Sci Transl Med. 2016 Jun 29;8(345):345ps14. doi: 10.1126/scitranslmed.aaf0756. Review.

PMID:
27358496
35.

Future Challenges for Vaccinologists.

Thomas S, Dilbarova R, Rappuoli R.

Methods Mol Biol. 2016;1403:41-55. doi: 10.1007/978-1-4939-3387-7_2.

PMID:
27076124
36.

Erratum for Baddal et al., Dual RNA-seq of Nontypeable Haemophilus influenzae and Host Cell Transcriptomes Reveals Novel Insights into Host-Pathogen Cross Talk.

Baddal B, Muzzi A, Censini S, Calogero RA, Torricelli G, Guidotti S, Taddei AR, Covacci A, Pizza M, Rappuoli R, Soriani M, Pezzicoli A.

MBio. 2016 Apr 12;7(2):e00373-16. doi: 10.1128/mBio.00373-16. No abstract available.

37.

Auto-Assembling Detoxified Staphylococcus aureus Alpha-Hemolysin Mimicking the Wild-Type Cytolytic Toxin.

Fiaschi L, Di Palo B, Scarselli M, Pozzi C, Tomaszewski K, Galletti B, Nardi-Dei V, Arcidiacono L, Mishra RP, Mori E, Pallaoro M, Falugi F, Torre A, Fontana MR, Soriani M, Bubeck Wardenburg J, Grandi G, Rappuoli R, Ferlenghi I, Bagnoli F.

Clin Vaccine Immunol. 2016 Jun 6;23(6):442-50. doi: 10.1128/CVI.00091-16. Print 2016 Jun.

38.

Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design.

Rappuoli R, Bottomley MJ, D'Oro U, Finco O, De Gregorio E.

J Exp Med. 2016 Apr 4;213(4):469-81. doi: 10.1084/jem.20151960. Epub 2016 Mar 28. Review.

39.

Strategic Planning in Population Health and Public Health Practice: A Call to Action for Higher Education.

Phelps C, Madhavan G, Rappuoli R, Levin S, Shortliffe E, Colwell R.

Milbank Q. 2016 Mar;94(1):109-25. doi: 10.1111/1468-0009.12182.

40.

Staphylococcus aureus coagulase R domain, a new evasion mechanism and vaccine target.

Pozzi C, Bagnoli F, Rappuoli R.

J Exp Med. 2016 Mar 7;213(3):292. doi: 10.1084/jem.2133insight1. No abstract available.

41.

Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined.

Biagini M, Spinsanti M, De Angelis G, Tomei S, Ferlenghi I, Scarselli M, Rigat F, Messuti N, Biolchi A, Muzzi A, Anderloni G, Brunelli B, Cartocci E, Buricchi F, Tani C, Stella M, Moschioni M, Del Tordello E, Colaprico A, Savino S, Giuliani MM, Delany I, Pizza M, Costantino P, Norais N, Rappuoli R, Masignani V.

Proc Natl Acad Sci U S A. 2016 Mar 8;113(10):2714-9. doi: 10.1073/pnas.1521142113. Epub 2016 Feb 17.

42.

Self-assembling protein nanoparticles in the design of vaccines.

López-Sagaseta J, Malito E, Rappuoli R, Bottomley MJ.

Comput Struct Biotechnol J. 2015 Nov 26;14:58-68. doi: 10.1016/j.csbj.2015.11.001. eCollection 2016. Review.

43.

One Dose of Staphylococcus aureus 4C-Staph Vaccine Formulated with a Novel TLR7-Dependent Adjuvant Rapidly Protects Mice through Antibodies, Effector CD4+ T Cells, and IL-17A.

Mancini F, Monaci E, Lofano G, Torre A, Bacconi M, Tavarini S, Sammicheli C, Arcidiacono L, Galletti B, Laera D, Pallaoro M, Tuscano G, Fontana MR, Bensi G, Grandi G, Rossi-Paccani S, Nuti S, Rappuoli R, De Gregorio E, Bagnoli F, Soldaini E, Bertholet S.

PLoS One. 2016 Jan 26;11(1):e0147767. doi: 10.1371/journal.pone.0147767. eCollection 2016.

44.

Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens.

Knudsen NP, Olsen A, Buonsanti C, Follmann F, Zhang Y, Coler RN, Fox CB, Meinke A, D'Oro U, Casini D, Bonci A, Billeskov R, De Gregorio E, Rappuoli R, Harandi AM, Andersen P, Agger EM.

Sci Rep. 2016 Jan 21;6:19570. doi: 10.1038/srep19570.

45.

Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood.

Nakaya HI, Clutterbuck E, Kazmin D, Wang L, Cortese M, Bosinger SE, Patel NB, Zak DE, Aderem A, Dong T, Del Giudice G, Rappuoli R, Cerundolo V, Pollard AJ, Pulendran B, Siegrist CA.

Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):1853-8. doi: 10.1073/pnas.1519690113. Epub 2016 Jan 11.

46.

The role of structural proteomics in vaccine development: recent advances and future prospects.

Donnarumma D, Faleri A, Costantino P, Rappuoli R, Norais N.

Expert Rev Proteomics. 2016;13(1):55-68. doi: 10.1586/14789450.2016.1121113. Review.

PMID:
26714563
47.

Dual RNA-seq of Nontypeable Haemophilus influenzae and Host Cell Transcriptomes Reveals Novel Insights into Host-Pathogen Cross Talk.

Baddal B, Muzzi A, Censini S, Calogero RA, Torricelli G, Guidotti S, Taddei AR, Covacci A, Pizza M, Rappuoli R, Soriani M, Pezzicoli A.

MBio. 2015 Nov 17;6(6):e01765-15. doi: 10.1128/mBio.01765-15. Erratum in: MBio. 2016;7(2). pii: e00373-16. doi: 10.1128/mBio.00373-16.

48.

Influence of Statins on Influenza Vaccine Response in Elderly Individuals.

Black S, Nicolay U, Del Giudice G, Rappuoli R.

J Infect Dis. 2016 Apr 15;213(8):1224-8. doi: 10.1093/infdis/jiv456. Epub 2015 Oct 28.

PMID:
26516142
49.

Oil-in-Water Emulsion MF59 Increases Germinal Center B Cell Differentiation and Persistence in Response to Vaccination.

Lofano G, Mancini F, Salvatore G, Cantisani R, Monaci E, Carrisi C, Tavarini S, Sammicheli C, Rossi Paccani S, Soldaini E, Laera D, Finco O, Nuti S, Rappuoli R, De Gregorio E, Bagnoli F, Bertholet S.

J Immunol. 2015 Aug 15;195(4):1617-27. doi: 10.4049/jimmunol.1402604. Epub 2015 Jul 13.

50.

Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2.

Ahmed SS, Volkmuth W, Duca J, Corti L, Pallaoro M, Pezzicoli A, Karle A, Rigat F, Rappuoli R, Narasimhan V, Julkunen I, Vuorela A, Vaarala O, Nohynek H, Pasini FL, Montomoli E, Trombetta C, Adams CM, Rothbard J, Steinman L.

Sci Transl Med. 2015 Jul 1;7(294):294ra105. doi: 10.1126/scitranslmed.aab2354.

PMID:
26136476

Supplemental Content

Loading ...
Support Center